IMPROVE-IT Go-Ahead Gives Merck Temporary Reprieve On Vytorin

Large outcomes study of Vytorin (ezetimibe/simvastatin) is allowed to carry on, reassuring investors that significant safety problems are unlikely to emerge. The development coincides with release of full results from the outcomes trial HPS2-THRIVE, in which Merck’s niacin-containing Tredaptive proved unsafe as well as ineffective.